Tiankang Biotech (002100.SZ) issued an advance loss. The net loss for half a year is estimated to be worth 400 million yuan to 520 million yuan

According to the Zhitong Finance App, Tiankang Biotech (002100.SZ) released the 2026 semi-annual results forecast. The company expects to achieve a loss of 400 million yuan to 520 million yuan in net profit attributable to shareholders of listed companies in the 2026 half year, changing from profit to loss over the previous year.

During the reporting period, the number of pigs released was 1.848,400 (including data released by the holding subsidiary Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. in June 2026), an increase of 20.95% over the same period last year. The pig market continued to be sluggish during the reporting period. The sales price of pigs dropped sharply compared to the same period last year, and the pig breeding business experienced phased losses; the pharmaceutical business experienced a major decline due to multiple factors such as the market environment, the downstream breeding industry, and the increase in value-added tax rates for biological products.